Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KínaFázis nélkül

Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China

A legfontosabb adatok

Ki végzi
Xijing Hospital
Hol
Beijing, Chengdu, Shanghai és Xi'an (Kína)Mind a 4 helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
450 fő, tervezett
Kezdés
2025. ápr. 24.
Várható befejezés
2031. jún. 30.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • Transcatheter Aortic Valve Replacement (TAVR)
A regiszteradat frissítve
2026. május 27.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults in China aged 50 to 70 with severe aortic valve narrowing (aortic stenosis). They have a new valve put in through a blood vessel (Sapien 3 TAVR).

Életkor
50 to 70 years
Nem
All sexes
A betegség stádiuma
Severe aortic stenosis, with or without symptoms, measured by heart ultrasound (for example valve area ≤1.0 cm2, mean gradient ≥40 mm Hg or valve velocity ≥4.0 m/sec). The valve must have three leaflets or be a type-1 two-leaflet (bicuspid) valve, shown by CT scan. Blood vessels in the groin must allow the valve to be put in safely.
Korábbi kezelés
People who already have a mechanical or tissue artificial heart valve cannot join.

A részvétel fő kizáró okai

  • Heart attack in the last 1 month (30 days), or stroke or TIA within 180 days
  • Need for open heart surgery, or other valve types (unicuspid, type-0 or type-2 bicuspid, quadricuspid)
  • Heart pumping strength (LVEF) below 30%, or hypertrophic cardiomyopathy
  • Kidney replacement treatment (such as dialysis) at screening, or severe lung disease or home oxygen
  • Life expectancy under 24 months, or allergy or inability to take heparin, contrast dye, warfarin or NOAC, aspirin or clopidogrel

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • Subjects must meet ALL of the following inclusion criteria to be eligible for participation:
  • 50 years of age or older but ≤70 years old at time of consent
  • Severe AS, defined as follows:; For symptomatic patients: i) Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), OR mean gradient ≥40 mm Hg, OR Maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest b) For asymptomatic patients: i) Very severe AS with an aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND maximal aortic velocity ≥5.0 m/sec, or mean gradient ≥60 mm Hg by transthoracic echocardiography at rest, OR ii) Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND a mean gradient ≥40 mm Hg or maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest, AND an exercise tolerance test that demonstrates a limited exercise capacity, abnormal BP response, or arrhythmia OR iii) Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND mean gradient ≥40 mmHg, or maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest, AND a left ventricular ejection fraction <50%
  • Tricuspid aortic valve stenosis and type-1 bicuspid aortic valve anatomy confirmed by MDCT
  • The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits
  • Adequate iliofemoral access and acceptable level of vessel calcification and tortuosity for safe device implant
  • The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site

Ki nem vehet részt

  • Emergency interventional/surgical procedures within 30 days of the valve implant procedure
  • Renal replacement therapy at the time of screening
  • Severe lung disease (FEV1 < 50% predicted) or currently on home oxygen
  • Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials. Observational studies are not considered exclusionary
  • Evidence of an acute myocardial infarction ≤ 1 month (30 days), with evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia
  • Need for open heart surgery (including severe aortic regurgitation, mitral regurgitation or stenosis, or tricuspid regurgitation, congenital heart disease, AF, complex coronary artery disease)
  • Aortic disease: a. bicuspid aortic valve with an ascending aorta diameter ≥ 45mm b. tricuspid aortic valve with an ascending aorta diameter ≥ 50mm
  • Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of the screening visit
  • Cardiac imaging (echo, CT, and/or MRI) evidence of ventricular mass, thrombus or vegetation
  • Inability (including allergy) to heparin, iodine contrast agent, warfarin or NOAC, aspirin or clopidogrel
  • Stroke or transient ischemic attack (TIA) within 180 days of the valve implant procedure
  • Ventricular dysfunction with LVEF < 30%
  • Subjects are NOT eligible for participation if they meet ANY of the following exclusion criteria:
  • Any of the following: a. no calcification; b. challenging calcification based on physician's experience and discretion (Case Review Board would decide whether to exclude challenging calcification cases)
  • Aortic valve is a congenital unicuspid valve, congenital Type-0 or Type-2 bicuspid valve, or quadricuspid valve
  • Severe femoral, iliac or aortic atherosclerosis, calcification, coarctation, aneurysm or tortuosity, which prevents transfemoral TAVR
  • Pre-existing mechanical or bioprosthetic valve in any position
  • Hypertrophic cardiomyopathy with or without obstruction
  • Estimated life expectancy < 24 months

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 50 és 70 év között vagy?

Helyszínek itt: Kína

  • Fuwai Hospital Chinese Academy of Medical SciencesBeijing, KínaContact: Xiangbin Pan, MD, PhDToborzás még nem indult
  • West China Hospital,Sichuan UniversityChengdu, KínaContact: Yingqiang Guo, MD, PhDToborzás még nem indult
  • Shanghai Zhongshan Hospital, Fudan UniversityShanghai, KínaContact: Lai Wei, MD, PhDRésztvevőt keres
  • Department of Cardiovascular Surgery of Xijing Hospital, Air Force Military Medical UniversityXi'an, KínaContact: Jian Yang, MD, PhDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Safety, effectiveness and durability of Sapien 3 transcatheter aortic valve replacement in young aortic valve stenosis patients from China:A multi-center, retrospective and prospective, single arm, observational study

A vizsgálat 2 csoportja

  • 300 retrospectively enrolled patients

    Procedure: TAVR

    Kezelés: Transcatheter Aortic Valve Replacement (TAVR)

  • 150 prospectively enrolled patients

    Procedure: TAVR

    Kezelés: Transcatheter Aortic Valve Replacement (TAVR)

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Safety, Effectiveness and Durability of Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT06830499: ki vehet részt
A regiszteradat frissítve
2026. május 27.